132622-91-4

Usage

Chemical class

Pyrrolidine-2,4-dicarboxylate esters

Stereochemistry

Chiral compound with a specific stereochemistry (2S,4S)

Common use

Pharmaceutical research and drug development

Role

Building block in the synthesis of various pharmacologically active molecules

Biological activities

Exhibits diverse biological activities

Potential therapeutic properties

Shown potential in the treatment of various diseases

Upstream product

• 132622-90-3 (2S,4S)-2-benzyl 1-tert-butyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 124-63-0 methanesulfonyl chloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 132622-88-9 (2S,4S)-4-Hydroxy-pyrrolidine-2-carboxylic acid benzyl ester 
• 87250-97-3 tert-butyl 3-oxo-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxylate 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 87691-27-8 N-tert-butoxycarbonyl-L-cis-4-hydroxyproline 
• 51-35-4 4R-4-hydroxyproline 

Downstream Products

• 958879-77-1 N-tert-butyloxycarbonyl-(2S,4R)-4-thioproline 
• 176306-18-6 [R-(R*,S*)]-4-[(Triphenylmethyl)thio]-1,2-pyrrolidinedicarboxylic acid, 1-(1,1-dimethylethyl) ester 
• 958879-76-0 N-tert-butyloxycarbonyl-(2S,4R)-4-thioacetyl-proline benzyl ester 
• 132622-96-9 (4S)-1-(tert-butoxycarbonyl)-4-<<<<(p-toluenesulfonyl)imino>aminomethyl>amino>methyl>-L-proline 
• 132622-95-8 (4R)-1-(tert-butoxycarbonyl)-4-(aminomethyl)-L-proline 
• 132622-94-7 (4R)-1-(tert-butoxycarbonyl)-4-cyano-L-proline benzyl ester 

Relevant academic research and scientific papers

Dual kinetically controlled native chemical ligation using a combination of sulfanylproline and sulfanylethylanilide peptide

Dual kinetically controlled native chemical ligation using a newly developed sulfanylproline-mediated reaction in combination with an N-sulfanylethylanilide peptide was successfully applied to a previously unreported sequential coupling of peptide fragments added simultaneously to the reaction.

Chimeric amino acid analogues

A chimeric amino acid analogue is provided suitable for incorporating into peptides which compound is represented by Formula 1: STR1 where P1 is preferably an amine protecting agent, and P2 and P3 are preferably amine or guanidine protecting agents. X can be OH, halide, or preferably an activating group suitable for conjugating the compound of Formula 1 to a peptide by conventional means, and m and n are 0-1 and 0-2 respectively. Peptides containing the chimeric amino acid analog are provided and include a platelet-aggregation inhibitor represented by where Aaa1 is Gly or H, Cpdl is the compound of Formula 1 which has been deprotected and Aaa2 is a hydrophobic amino acid preferably Val.

Conformationally Restricted Arginine Analogues

We report the practical synthesis and structural characterization of a set of conformationally constrained protected arginine analogues.These enantiomerically pure analogues have the general structure 1 and are prepared in seven to eight steps from the co